Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients
NCT04398732
Last updated date
ABOUT THIS STUDY
This study is to evaluate available local data in Iraqi patients with moderate to severe
psoriasis on Enbrel treatment with regards to efficacy, treatment regimen adherence and
patient characterization (i.e. age, gender, smoking status) using data from the
Dermatologists in Baghdad Teaching Hospital registry
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Plaque Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Confirmed diagnosis of moderate to severe plaque psoriasis receiving etanercept treatment for a minimum duration of 1 year.
- Age ≥18 years old.
- No history of using a biological treatment, other than etanercept, for treatment of moderate to severe plaque psoriasis or any other reason.
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Etanercept use for treatment moderate to severe plaque psoriasis less than 1 year
duration.
- Previous use of other biological treatments for any reason
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Plaque PsoriasisStudy To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).
NCT04428411
- Baghdad,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Plaque PsoriasisStudy to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients
NCT04398732
- Baghdad,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Plaque PsoriasisStudy Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis
NCT01710046
- Los Angeles, California
- Tampa, Florida
- Dallas, Texas
- Houston, Texas
- Houston, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Plaque PsoriasisStudy Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
NCT01010542
- Miami Gardens, Florida
- South Miami, Florida
- Indianapolis, Indiana
- Fort Gratiot, Michigan
- Winston-Salem, North Carolina
- Greer, South Carolina
- St John's, Newfoundland and Labrador
- Waterloo, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | |||||
|---|---|---|---|---|---|
| Brief Title | Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients | ||||
| Official Title | Efficacy of Etanercept in Iraqi Patients With Moderate to Severe Psoriasis: 5 Years Data From Local Registry. | ||||
| Brief Summary | This study is to evaluate available local data in Iraqi patients with moderate to severe psoriasis on Enbrel treatment with regards to efficacy, treatment regimen adherence and patient characterization (i.e. age, gender, smoking status) using data from the Dermatologists in Baghdad Teaching Hospital registry | ||||
| Detailed Description | Not Provided | ||||
| Study Type | Observational | ||||
| Study Design | Observational Model: Cohort Time Perspective: Retrospective | ||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Not Provided | ||||
| Sampling Method | Non-Probability Sample | ||||
| Study Population | Patients data from the local registry at the Dermatology Center of Baghdad Teaching Hospital registry. | ||||
| Condition | Plaque Psoriasis | ||||
| Intervention | Drug: Enbrel
As provided in real world practice | ||||
| Study Groups/Cohorts | Patients with moderate to severe plaque psoriasis
Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease. Intervention: Drug: Enbrel | ||||
| Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
| Recruitment Information | |||||
| Recruitment Status | Completed | ||||
| Actual Enrollment | 1 | ||||
| Original Estimated Enrollment | Same as current | ||||
| Actual Study Completion Date | October 1, 2020 | ||||
| Actual Primary Completion Date | October 1, 2020 (Final data collection date for primary outcome measure) | ||||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| ||||
| Sex/Gender |
| ||||
| Ages | 18 Years and older (Adult, Older Adult) | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
| Listed Location Countries | Iraq | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number | NCT04398732 | ||||
| Other Study ID Numbers | B1801412 | ||||
| Has Data Monitoring Committee | Not Provided | ||||
| U.S. FDA-regulated Product | Not Provided | ||||
| IPD Sharing Statement |
| ||||
| Responsible Party | Pfizer | ||||
| Study Sponsor | Pfizer | ||||
| Collaborators | Not Provided | ||||
| Investigators |
| ||||
| PRS Account | Pfizer | ||||
| Verification Date | October 2020 | ||||